ESR1 and breast carcinoma: With ER-positive breast cancers, endocrine therapies often become less effective in advanced disease; so PET imaging of ER with FES and ER functional status by serial FDG- or FFNP-PET with an estradiol challenge can provide additional predictive value for benefit from continued endocrine therapies.